# US 2026/0062422 A1 · Heterobifunctional compounds and methods of treating disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062422 A1
- Document ID: US20260062422A1
- Status: Published application
- Kind: A1
- Application number: 19/108,233
- Filed: 2023-09-08
- Published: 2026-03-05
- Earliest claimed: 2022-09-08
- Assignees: Halda Therapeutics OpCo, Inc.
- Applicants: Halda Therapeutics OpCo, Inc.
- Inventors: Kyle J. Eastman; Katherine J. Kayser-Bricker; Michael Barrington Martin; James John Mousseau; Matthew Alexander Perry; David E. Puleo; Kanak Shail Raina; Nilesh K. Zaware; Taavi Neklesa; Samuel W. Gerritz; Todd Bosanac
- Web page: https://patentgrep.com/patent/US20260062422A1

## CPC

- C07D 495/14: Ortho-condensed systems
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61P 35/00: Antineoplastic agents
- C07B 59/002: {Heterocyclic compounds}
- C07D 498/04: Ortho-condensed systems
- C07D 498/14: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The invention provides heterobifunctional compounds which may bind to both an androgen receptor and BRD4 (bromodomain-containing protein 4). Also provided are pharmaceutical compositions comprising the same and their use in treating disease, CN such as cancer.

## Claims

### Claim 1

A compound represented by Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is phenyl substituted by cyano, halogen, and m occurrences of R4;
R2 represents independently for each occurrence C1-4 alkyl;
R3 is hydrogen or C1-4 alkyl;
R4 is C1-4 alkyl;
R5 represents independently for each occurrence C1-4 alkyl or halogen; or one occurrence of R5 is taken together with R3 to form a C1-3 alkylene;
A1 is a pyridazinylene, pyrimidinylene, pyrazinylene, or pyridinylene, each of which is substituted with n occurrences of R5;
A2 is one of the following:
R1A is C1-4 alkyl or C3-4 cycloalkyl;
R2A represents independently for each occurrence C1-4 alkyl or C3-4 cycloalkyl;
R3A is phenyl substituted with 1, 2, or 3 substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl
R4A is —(C1-6 alkylene)-C(O)N(R5A)(R6A), —(C1-6 alkylene)-N(R5A)C(O)R7A, —(C1-6 alkylene)-CO2R8A, —(C1-6 alkylene)-OC(O)R7A, —(C1-6 alkylene)-CN, —(C1-6 alkylene)-O—(C1-6 alkyl), C1-6 alkyl, C3-6 cycloalkyl, or —(C0-6 alkylene)-(5-6 membered heteroaryl containing 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with 0, 1, or 2 occurrences of C1-6 alkyl);
R5A and R6A are independently hydrogen, C1-6 alkyl, or C3-6 cycloalkyl; or R5A and R6A are taken together with the nitrogen atom to which they are attached to form a 3-7 membered ring containing 1 nitrogen atom;
R7A is C1-6 alkyl, —(C1-6 alkylene)-(C3-6 cycloalkyl), or C3-6 cycloalkyl;
R8A is hydrogen, C1-6 alkyl, —(C1-6 alkylene)-(C3-6 cycloalkyl), or C3-6 cycloalkyl;
R9A is halo;
R10A represents independently for each occurrence C1-4 alkyl or —N(R11A)2;
R11A represents independently for each occurrence hydrogen or C1-4 alkyl;
R12A is —(C0-6 alkylene)-(5-6 membered heteroaryl containing 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with 0, 1, or 2 occurrences of C1-6 alkyl);
L is a bivalent, saturated or unsaturated, straight or branched C1-60 hydrocarbon chain, wherein 0-20 methylene units of the hydrocarbon are independently replaced with —O—, —S—, —N(H)—, —N(C1-6 alkyl)-, —OC(O)—, —C(O)O—, —S(O)—, —S(O)2—, —N(H)S(O)2—, —N(C1-6 alkyl)S(O)2—, —S(O)2N(H)—, —S(O)2N(C1-6 alkyl)-, —N(H)C(O)—, —N(C1-6 alkyl)C(O)—, —C(O)N(H)—, —C(O)N(C1-6 alkyl)-, —OC(O)N(H)—, —OC(O)N(C1-6 alkyl)-, —N(H)C(O)O—, —N(C1-6 alkyl)C(O)O—, —N(C3-7 cycloalkyl)-, optionally substituted 3-10 membered carbocyclyl, or optionally substituted 3-10 membered heterocyclyl containing 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
k is 1, 2, 3, or 4;
m, n, p, and q are independently 0, 1, or 2; and
s is 1 or 2.

### Claim at position 2

2-4. (canceled)

### Claim 5 (depends on 1)

The compound of claim 1, wherein R1 is

### Claim at position 4

6-7. (canceled)

### Claim 8 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula Ia or a pharmaceutically acceptable salt thereof:

### Claim at position 6

9-10. (canceled)

### Claim 11 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula Id or a pharmaceutically acceptable salt thereof:

### Claim at position 8

12-21. (canceled)

### Claim 22 (depends on 8)

The compound of claim 8, wherein A2 is

### Claim 23

(canceled)

### Claim 24 (depends on 8)

The compound of claim 8, wherein A2 is

### Claim at position 12

25-34. (canceled)

### Claim 35 (depends on 8)

The compound of claim 8, wherein A2 is

### Claim 36 (depends on 8)

The compound of claim 8, wherein A2 is

### Claim 37 (depends on 8)

The compound of claim 8, wherein A2 is

### Claim at position 16

38-45. (canceled)

### Claim 46

A compound represented by Formula I*:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is phenyl substituted by cyano, halogen, and m occurrences of R4;
R2 represents independently for each occurrence C1-4 alkyl;
R3 is hydrogen or C1-4 alkyl;
R4 is C1-4 alkyl;
R5 represents independently for each occurrence C1-4 alkyl or halogen; or one occurrence of R5 is taken together with R3 to form a C1-3 alkylene;
A1 is a pyridazinylene, pyrimidinylene, pyrazinylene, or pyridinylene, each of which is substituted with n occurrences of R5;
A2 is
R1A is C1-4 alkyl or C3-4 cycloalkyl;
R2A represents independently for each occurrence C1-4 alkyl or C3-4 cycloalkyl;
R3A is phenyl substituted with 1, 2, or 3 substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl
R4A is C1-6 hydroxyalkyl, C1-4 haloalkyl, —(C1-6 alkylene)-C(O)N(R5A)(R6A), —(C1-6 alkylene)-N(R5A)C(O)R7A, —(C1-6 alkylene)-CO2R8A, —(C1-6 alkylene)-OC(O)R7A, —(C1-6 alkylene)-CN, —(C1-6 alkylene)-O—(C1-6 alkyl), C1-6 alkyl, C3-6 cycloalkyl, or —(C0-6 alkylene)-(5-6 membered heteroaryl containing 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with 0, 1, or 2 occurrences of C1-6 alkyl);
R5A and R6A are independently hydrogen, C1-6 alkyl, or C3-6 cycloalkyl; or R5A and R6A are taken together with the nitrogen atom to which they are attached to form a 3-7 membered ring containing 1 nitrogen atom;
R7A is C1-6 alkyl, —(C1-6 alkylene)-(C3-6 cycloalkyl), or C3-6 cycloalkyl;
R8A is hydrogen, C1-6 alkyl, —(C1-6 alkylene)-(C3-6 cycloalkyl), or C3-6 cycloalkyl;
R9A is halo;
R10A is hydrogen or C1-4 alkyl; or R4A and R10A are taken together with the carbon atom to which they are attached to form a 3-5 membered saturated carbocylic ring;
L is a bivalent, saturated or unsaturated, straight or branched C1-60 hydrocarbon chain, wherein 0-20 methylene units of the hydrocarbon are independently replaced with —O—, —S—, —N(H)—, —N(C1-6 alkyl)-, —OC(O)—, —C(O)O—, —S(O)—, —S(O)2—, —N(H)S(O)2—, —N(C1-6 alkyl)S(O)2—, —S(O)2N(H)—, —S(O)2N(C1-6 alkyl)-, —N(H)C(O)—, —N(C1-6 alkyl)C(O)—, —C(O)N(H)—, —C(O)N(C1-6 alkyl)-, —OC(O)N(H)—, —OC(O)N(C1-6 alkyl)-, —N(H)C(O)O—, —N(C1-6 alkyl)C(O)O—, —N(C3-7 cycloalkyl)-, optionally substituted 3-10 membered carbocyclyl, or optionally substituted 3-10 membered heterocyclyl containing 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
k is 1, 2, 3, or 4; and
m, n, p, and q are independently 0, 1, or 2.

### Claim at position 18

47-48. (canceled)

### Claim 49 (depends on 1)

The compound of claim 1, wherein L is a bivalent,
saturated, straight or branched C3-30 hydrocarbon chain, wherein 0-15 methylene units of the hydrocarbon are independently replaced with —O—, —N(H)—, —N(C1-6 alkyl)-, —OC(O)—, —C(O)O—, —N(H)C(O)—, —N(C1-6 alkyl)C(O)—, —C(O)N(H)—, —C(O)N(C1-6 alkyl)-, 3-10 membered carbocyclyl, or 3-10 membered heterocyclyl containing 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

### Claim 50 (depends on 1)

The compound of claim 1, wherein L is a bivalent, saturated, straight or branched C3-30 hydrocarbon chain, wherein 0-15 methylene units of the hydrocarbon are independently replaced with —O—, —N(H)—, —N(C1-6 alkyl)-, —OC(O)—, —C(O)O—, —N(H)C(O)—, —N(C1-6 alkyl)C(O)—, —C(O)N(H)—, or —C(O)N(C1-6 alkyl)-.

### Claim 51

(canceled)

### Claim 52 (depends on 1)

The compound of claim 1, wherein L is -(3-7 membered, monocyclic, saturated heterocyclic ring containing 1 or 2 heteroatoms selected from nitrogen)-(OCH2CH2)1-15—O—***, wherein *** is the point of attachment to A2.

### Claim at position 23

53-54. (canceled)

### Claim 55 (depends on 1)

The compound of claim 1, wherein L is -piperidinylene-(OCH2CH2)1-15—O—*** wherein *** is the point of attachment to A2.

### Claim at position 25

56-87. (canceled)

### Claim 88 (depends on 1)

The compound of claim 1, wherein L is —N(CH3)—[(CH2CH2)—O—]2-8—(C2-6 alkylene)-N(H)C(O)—(C1-6 alkylene)-***, —N(CH3)—[(CH2CH2)—O—]2-8—(C2-6 alkylene)-N(CH3)C(O)—(C1-6 alkylene)-***, —N(H)—[(CH2CH2)—O—]2-8—(C2-6 alkylene)-N(H)C(O)—(C1-6 alkylene)-***, or —N(H)—[(CH2CH2)—O—]2-8—(C2-6 alkylene)-N(H)C(O)—(C1-6 alkylene)-***, where *** is a point of attachment to A2.

### Claim at position 27

89-113. (canceled)

### Claim 114 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 115 (depends on 1)

A method of treating cancer, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 to treat the cancer.

### Claim 116 (depends on 115)

The method of claim 115, wherein the cancer is ovarian cancer, uterine cancer, endometrial cancer, cervical cancer, prostate cancer, testicular cancer, breast cancer, brain cancer, lung cancer, oral cancer, esophageal cancer, head and neck cancer, stomach cancer, colon cancer, rectal cancer, skin cancer, sebaceous gland carcinoma, bile duct cancer, gallbladder cancer, liver cancer, pancreatic cancer, bladder cancer, urinary tract cancer, kidney cancer, eye cancer, thyroid cancer, lymphoma, or leukemia.

### Claim 117 (depends on 115)

The method of claim 115, wherein the cancer is prostate cancer.

### Claim 118 (depends on 1)

A method of causing death of a cancer cell, comprising contacting a cancer cell with an effective amount of a compound of claim 1 to cause death of the cancer cell.

### Claim 119 (depends on 118)

The method of claim 118, wherein the cancer cell is selected from an ovarian cancer, uterine cancer, endometrial cancer, cervical cancer, prostate cancer, testicular cancer, breast cancer, brain cancer, lung cancer, oral cancer, esophageal cancer, head and neck cancer, stomach cancer, colon cancer, rectal cancer, skin cancer, sebaceous gland carcinoma, bile duct cancer, gallbladder cancer, liver cancer, pancreatic cancer, bladder cancer, urinary tract cancer, kidney cancer, eye cancer, thyroid cancer, lymphoma, or leukemia cell.

### Claim 120

(canceled)
